PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31685558-1	2019	OBJECTIVE: To report results from an integrated efficacy and safety analysis supporting the European Commission"s approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.	Platinum	217-225	poly(ADP-ribose) polymerase 1	Homo sapiens	130-157